Atara Historical Financial Ratios

ATRA Stock

USD 12.26 0.14 1.16%

Atara Biotherapeutics is presently reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 1.5 K or Invested Capital of 0.0 will help investors to properly organize and evaluate Atara Biotherapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

About Atara Financial Ratios Analysis

Atara BiotherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Atara Biotherapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Atara financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Atara Biotherapeutics history.

Atara Biotherapeutics Financial Ratios Chart

At present, Atara Biotherapeutics' ROIC is projected to slightly decrease based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 2.53, whereas PTB Ratio is forecasted to decline to (0.57).

Price To Sales Ratio Book Value Per Share Ev To Sales Inventory Turnover Net Debt To E B I T D A

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Atara Biotherapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Atara Biotherapeutics sales, a figure that is much harder to manipulate than other Atara Biotherapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Net Debt To E B I T D A

A leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA).

Most ratios from Atara Biotherapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Atara Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.At present, Atara Biotherapeutics' ROIC is projected to slightly decrease based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 2.53, whereas PTB Ratio is forecasted to decline to (0.57).

	2022	2023	2024 (projected)
Payables Turnover	2.12	2.41	2.53
Days Of Inventory On Hand	39.74	398.68	418.62

Payables Turnover Days Of Inventory On Hand

Atara Biotherapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		-0.21	-0.84	0.29	0.86	-0.09	0.31	-0.21	1.0	-0.11	-0.38	0.78	-0.45	-0.82	-0.87	-1.0	0.97	0.28	-0.34	-0.78	-0.24	-0.33	0.49	-0.38	0.22	-0.31
Ptb Ratio	-0.21		0.16	0.32	-0.23	-0.69	0.3	1.0	-0.22	-0.7	-0.33	-0.15	-0.51	0.16	0.39	0.22	-0.21	0.28	0.98	0.15	-0.27	0.98	-0.61	0.83	-0.95	0.98
Days Sales Outstanding	-0.84	0.16		-0.28	-0.99	0.13	-0.28	0.16	-0.82	0.15	0.74	-0.99	0.47	1.0	0.78	0.82	-0.72	-0.25	0.29	0.99	0.22	0.28	-0.42	0.07	-0.04	0.27
Book Value Per Share	0.29	0.32	-0.28		0.33	0.04	0.47	0.32	0.28	0.01	-0.41	0.27	-0.07	-0.27	-0.21	-0.28	0.27	-0.19	0.19	-0.27	-0.2	0.2	0.0	0.16	-0.38	0.16
Free Cash Flow Yield	0.86	-0.23	-0.99	0.33		-0.02	0.28	-0.23	0.84	-0.05	-0.71	0.98	-0.38	-0.99	-0.8	-0.84	0.75	0.16	-0.36	-0.98	-0.22	-0.36	0.44	-0.15	0.1	-0.35
Operating Cash Flow Per Share	-0.09	-0.69	0.13	0.04	-0.02		-0.18	-0.69	-0.08	0.99	0.31	-0.13	0.91	0.13	-0.07	0.08	-0.07	-0.71	-0.72	0.13	0.24	-0.72	0.25	-0.62	0.6	-0.75
Capex To Depreciation	0.31	0.3	-0.28	0.47	0.28	-0.18		0.3	0.31	-0.28	-0.3	0.26	-0.24	-0.27	-0.36	-0.31	0.3	0.04	0.23	-0.26	-0.83	0.24	0.07	0.22	-0.29	0.22
Pb Ratio	-0.21	1.0	0.16	0.32	-0.23	-0.69	0.3		-0.22	-0.7	-0.33	-0.15	-0.51	0.16	0.39	0.22	-0.21	0.28	0.98	0.15	-0.27	0.98	-0.61	0.83	-0.95	0.98
Ev To Sales	1.0	-0.22	-0.82	0.28	0.84	-0.08	0.31	-0.22		-0.11	-0.35	0.76	-0.44	-0.8	-0.87	-1.0	0.98	0.28	-0.33	-0.76	-0.24	-0.33	0.49	-0.4	0.23	-0.31
Free Cash Flow Per Share	-0.11	-0.7	0.15	0.01	-0.05	0.99	-0.28	-0.7	-0.11		0.33	-0.15	0.9	0.15	-0.06	0.11	-0.09	-0.66	-0.71	0.15	0.37	-0.72	0.28	-0.63	0.62	-0.74
Roic	-0.38	-0.33	0.74	-0.41	-0.71	0.31	-0.3	-0.33	-0.35	0.33		-0.78	0.44	0.76	0.24	0.35	-0.22	-0.03	-0.22	0.78	0.33	-0.22	0.17	-0.52	0.55	-0.21
Inventory Turnover	0.78	-0.15	-0.99	0.27	0.98	-0.13	0.26	-0.15	0.76	-0.15	-0.78		-0.46	-1.0	-0.74	-0.76	0.64	0.24	-0.27	-1.0	-0.21	-0.26	0.39	-0.01	0.0	-0.25
Net Income Per Share	-0.45	-0.51	0.47	-0.07	-0.38	0.91	-0.24	-0.51	-0.44	0.9	0.44	-0.46		0.47	0.29	0.44	-0.41	-0.8	-0.49	0.46	0.23	-0.49	-0.03	-0.39	0.43	-0.53
Days Of Inventory On Hand	-0.82	0.16	1.0	-0.27	-0.99	0.13	-0.27	0.16	-0.8	0.15	0.76	-1.0	0.47		0.77	0.8	-0.69	-0.25	0.28	1.0	0.22	0.28	-0.41	0.05	-0.03	0.26
Payables Turnover	-0.87	0.39	0.78	-0.21	-0.8	-0.07	-0.36	0.39	-0.87	-0.06	0.24	-0.74	0.29	0.77		0.87	-0.83	-0.35	0.48	0.74	0.13	0.48	-0.78	0.45	-0.41	0.45
Average Inventory	-1.0	0.22	0.82	-0.28	-0.84	0.08	-0.31	0.22	-1.0	0.11	0.35	-0.76	0.44	0.8	0.87		-0.98	-0.28	0.33	0.76	0.24	0.33	-0.49	0.4	-0.23	0.31
Capex To Revenue	0.97	-0.21	-0.72	0.27	0.75	-0.07	0.3	-0.21	0.98	-0.09	-0.22	0.64	-0.41	-0.69	-0.83	-0.98		0.27	-0.32	-0.65	-0.23	-0.32	0.48	-0.47	0.26	-0.3
Cash Per Share	0.28	0.28	-0.25	-0.19	0.16	-0.71	0.04	0.28	0.28	-0.66	-0.03	0.24	-0.8	-0.25	-0.35	-0.28	0.27		0.31	-0.24	0.12	0.31	0.38	0.16	-0.1	0.37
Pocfratio	-0.34	0.98	0.29	0.19	-0.36	-0.72	0.23	0.98	-0.33	-0.71	-0.22	-0.27	-0.49	0.28	0.48	0.33	-0.32	0.31		0.27	-0.21	1.0	-0.64	0.84	-0.91	1.0
Interest Coverage	-0.78	0.15	0.99	-0.27	-0.98	0.13	-0.26	0.15	-0.76	0.15	0.78	-1.0	0.46	1.0	0.74	0.76	-0.65	-0.24	0.27		0.21	0.26	-0.39	0.01	0.0	0.25
Capex To Operating Cash Flow	-0.24	-0.27	0.22	-0.2	-0.22	0.24	-0.83	-0.27	-0.24	0.37	0.33	-0.21	0.23	0.22	0.13	0.24	-0.23	0.12	-0.21	0.21		-0.22	0.24	-0.25	0.31	-0.2
Pfcf Ratio	-0.33	0.98	0.28	0.2	-0.36	-0.72	0.24	0.98	-0.33	-0.72	-0.22	-0.26	-0.49	0.28	0.48	0.33	-0.32	0.31	1.0	0.26	-0.22		-0.64	0.84	-0.91	1.0
Days Payables Outstanding	0.49	-0.61	-0.42	0.0	0.44	0.25	0.07	-0.61	0.49	0.28	0.17	0.39	-0.03	-0.41	-0.78	-0.49	0.48	0.38	-0.64	-0.39	0.24	-0.64		-0.62	0.69	-0.6
Income Quality	-0.38	0.83	0.07	0.16	-0.15	-0.62	0.22	0.83	-0.4	-0.63	-0.52	-0.01	-0.39	0.05	0.45	0.4	-0.47	0.16	0.84	0.01	-0.25	0.84	-0.62		-0.9	0.83
Roe	0.22	-0.95	-0.04	-0.38	0.1	0.6	-0.29	-0.95	0.23	0.62	0.55	0.0	0.43	-0.03	-0.41	-0.23	0.26	-0.1	-0.91	0.0	0.31	-0.91	0.69	-0.9		-0.89
Ev To Operating Cash Flow	-0.31	0.98	0.27	0.16	-0.35	-0.75	0.22	0.98	-0.31	-0.74	-0.21	-0.25	-0.53	0.26	0.45	0.31	-0.3	0.37	1.0	0.25	-0.2	1.0	-0.6	0.83	-0.89

Click cells to compare fundamentals

Atara Biotherapeutics Account Relationship Matchups

Atara Biotherapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	2.91	3.14	5.28	2.64	(0.55)	(0.57)
Book Value Per Share	141.68	156.25	74.63	31.04	(23.42)	(22.25)
Operating Cash Flow Per Share	(114.81)	(61.09)	(58.86)	(66.29)	(45.55)	(47.83)
Capex To Depreciation	0.81	0.54	1.13	0.74	0.25	0.24
Pb Ratio	2.91	3.14	5.28	2.64	(0.55)	(0.57)
Free Cash Flow Per Share	(117.6)	(62.61)	(61.68)	(67.32)	(45.84)	(48.13)
Roic	(1.02)	(0.67)	(1.22)	(2.22)	2.78	2.92
Net Income Per Share	(1.4K)	(1.0K)	(907.82)	(559.62)	(65.18)	(68.44)
Cash Per Share	126.25	169.2	99.04	59.52	12.21	11.6
Pocfratio	(3.59)	(8.03)	(6.69)	(1.24)	(0.28)	(0.3)
Capex To Operating Cash Flow	(0.0243)	(0.025)	(0.048)	(0.0155)	(0.006338)	(0.006654)
Pfcf Ratio	(3.5)	(7.84)	(6.39)	(1.22)	(0.28)	(0.29)
Days Payables Outstanding	358.61	263.31	557.06	172.15	151.32	143.76
Income Quality	0.73	0.78	0.81	1.18	0.7	0.55
Roe	(10.01)	(6.63)	(12.16)	(18.03)	2.78	2.92
Ev To Operating Cash Flow	(3.33)	(7.0)	(6.33)	(1.16)	(0.45)	(0.47)
Pe Ratio	(0.29)	(0.47)	(0.43)	(0.15)	(0.2)	(0.21)
Return On Tangible Assets	(8.48)	(5.21)	(7.27)	(6.07)	(1.67)	(1.75)
Ev To Free Cash Flow	(3.25)	(6.83)	(6.04)	(1.14)	(0.44)	(0.47)
Earnings Yield	(3.44)	(2.11)	(2.3)	(6.82)	(5.08)	(5.34)
Net Debt To E B I T D A	0.21	0.63	0.24	0.0994	(0.12)	(0.11)
Current Ratio	7.43	6.31	3.64	3.74	0.72	0.68
Tangible Book Value Per Share	141.68	156.25	74.63	31.04	(23.42)	(22.25)
Graham Number	2.1K	1.9K	1.2K	625.19	185.34	176.07
Shareholders Equity Per Share	141.68	156.25	74.63	31.04	(23.42)	(22.25)
Capex Per Share	2.79	1.53	2.82	1.03	0.29	0.27
Graham Net Net	100.84	127.01	48.92	5.88	(43.1)	(40.94)
Enterprise Value Over E B I T D A	(2.77)	(4.26)	(4.22)	(1.47)	(0.32)	(0.34)
Price Earnings Ratio	(0.29)	(0.47)	(0.43)	(0.15)	(0.2)	(0.21)
Price Book Value Ratio	2.91	3.14	5.28	2.64	(0.55)	(0.57)
Price Earnings To Growth Ratio	(0.0377)	0.0176	0.035	0.00382	(0.0119)	(0.0113)
Days Of Payables Outstanding	358.61	263.31	557.06	172.15	151.32	143.76
Price To Operating Cash Flows Ratio	(3.59)	(8.03)	(6.69)	(1.24)	(0.28)	(0.3)
Price To Free Cash Flows Ratio	(3.5)	(7.84)	(6.39)	(1.22)	(0.28)	(0.29)
Effective Tax Rate	(4.1E-5)	(4.9E-5)	(1.35E-4)	(5.3E-5)	(5.4E-5)	(5.7E-5)
Company Equity Multiplier	1.18	1.27	1.67	2.97	(1.67)	(1.58)
Return On Capital Employed	(0.67)	(0.97)	(0.61)	(0.94)	(11.86)	(11.26)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:

How To Invest In Atara

Details

Is Atara Stock a good investment?

Details

What is Atara Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(25.32)

Revenue Per Share

12.263

Quarterly Revenue Growth

28.927

Return On Assets

(0.57)

Return On Equity

(20.15)

The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Atara Historical Financial Ratios

About Atara Financial Ratios Analysis

Atara Biotherapeutics Financial Ratios Chart

Price To Sales Ratio

Book Value Per Share

Ev To Sales

Inventory Turnover

Net Debt To E B I T D A

Atara Biotherapeutics fundamentals Correlations

Atara Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Atara Biotherapeutics fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Days Of Inventory On Hand	+ 1.0	Days Sales Outstanding
Interest Coverage	+ 1.0	Days Of Inventory On Hand
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio

Interest Coverage	- 1.0	Inventory Turnover
Days Of Inventory On Hand	- 1.0	Inventory Turnover
Average Inventory	- 1.0	Ev To Sales
Average Inventory	- 1.0	Price To Sales Ratio
Days Of Inventory On Hand	- 0.99	Free Cash Flow Yield
Inventory Turnover	- 0.99	Days Sales Outstanding